Company news

Island Pharmaceuticals Ltd news in 2025

Island Pharmaceuticals Ltd's news releases, calls and decks from 2025, newest first.

View company

Agreement with Texas Biomed for Galidesivir Program

December 16, 2025

Island expands Galidesivir IP with US Patent Grant

December 4, 2025

Additional FDA Submission completed for Galidesivir

December 3, 2025

Options exercised raises $1million

December 2, 2025

Coalition acceptance to advance US procurement & stockpiling

November 23, 2025

Island engages advisers to advance biodefence strategy

November 19, 2025

FDA agrees Animal Rule pathway and PRV eligibility

November 16, 2025

FDA confirms response timing for Galidesivir

October 21, 2025

US FDA Type C meeting briefing document submitted

September 28, 2025

FDA Meeting request granted

September 18, 2025

FDA meeting request lodged for Galidesivir

August 31, 2025

Preliminary Final Report

August 28, 2025

Options exercise from existing substantial shareholder

August 11, 2025

Completion of Galidesivir transaction

July 30, 2025

Portfolio expansion achieved with acquisition of Galidesivir

July 8, 2025

Successful Phase 2 clinical trial of ISLA-101

June 12, 2025

Island completes $3.6 million placement

May 20, 2025

Quarterly Activities & Cashflow Report

April 29, 2025

Phase 2a/b clinical trial update

April 22, 2025

Completion of patient dosing in Phase 2b clinical trial

February 11, 2025

Completion of enrolment in Phase 2b arm

January 21, 2025

ISLA-101 Phase 2b clinical trial enrols first subjects

January 7, 2025

Decks in 2025